select a format

Single User License
USD 2000 INR 130040
Site License
USD 4000 INR 260080
Corporate User License
USD 6000 INR 390120


Request a quote
Request a Customized research
Request for Sample Report


Recent Viewed Reports

Why Ken Reasearch?


The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

Kidney Fibrosis-Pipeline Review, H1 2015

Kidney Fibrosis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6602IDB
  • |
  • Pages: 93
  • |
  • April 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Kidney Fibrosis-Pipeline Review, H1 2015


Global Markets Direct's, 'Kidney Fibrosis-Pipeline Review, H1 2015', provides an overview of the Kidney Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Kidney Fibrosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Kidney Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Kidney Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Kidney Fibrosis Overview 8

Therapeutics Development 9

Pipeline Products for Kidney Fibrosis-Overview 9

Pipeline Products for Kidney Fibrosis-Comparative Analysis 10

Kidney Fibrosis-Therapeutics under Development by Companies 11

Kidney Fibrosis-Therapeutics under Investigation by Universities/Institutes 12

Kidney Fibrosis-Pipeline Products Glance 13

Early Stage Products 13

Kidney Fibrosis-Products under Development by Companies 14

Kidney Fibrosis-Products under Investigation by Universities/Institutes 15

Kidney Fibrosis-Companies Involved in Therapeutics Development 16

AbbVie Inc. 16

Angion Biomedica Corp. 17

Bio-inRen 18

BioLineRx, Ltd. 19

BiOrion Technologies B.V. 20

Galectin Therapeutics, Inc. 21

GNI Group Ltd. 22

Lpath, Inc. 23

ProMetic Life Sciences Inc. 24

Raptor Pharmaceuticals Corp. 25

Regulus Therapeutics Inc. 26

RestorGenex Corporation 27

Tobira Therapeutics, Inc. 28

Kidney Fibrosis-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

ANG-3298-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

ANG-4011-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

BOT-191-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

BRN-1889-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

cenicriviroc mesylate-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CGEN-856-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

CT-140-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

cysteamine DR-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

F-351-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

GR-MD-02-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

ICG-001-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

LJ-1888-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Lpathomab-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

P-007-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

P-529-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

PBI-4050-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

RG-012-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

SOL-1-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

SphK2 Program-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Kidney Fibrosis-Recent Pipeline Updates 67

Kidney Fibrosis-Dormant Projects 88

Kidney Fibrosis-Product Development Milestones 89

Featured News & Press Releases 89

Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting 89

Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 89

Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 90

Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan 90

Aug 26, 2010: GNI Receives F351 Patent Allowance in Canada 90

Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI's Key Therapeutic Product for Liver Disease 91

Appendix 92

Methodology 92

Coverage 92

Secondary Research 92

Primary Research 92

Expert Panel Validation 92

Contact Us 92

Disclaimer 93

List of Tables

Number of Products under Development for Kidney Fibrosis, H1 2015 9

Number of Products under Development for Kidney Fibrosis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Products under Investigation by Universities/Institutes, H1 2015 15

Kidney Fibrosis-Pipeline by AbbVie Inc., H1 2015 16

Kidney Fibrosis-Pipeline by Angion Biomedica Corp., H1 2015 17

Kidney Fibrosis-Pipeline by Bio-inRen, H1 2015 18

Kidney Fibrosis-Pipeline by BioLineRx, Ltd., H1 2015 19

Kidney Fibrosis-Pipeline by BiOrion Technologies B.V., H1 2015 20

Kidney Fibrosis-Pipeline by Galectin Therapeutics, Inc., H1 2015 21

Kidney Fibrosis-Pipeline by GNI Group Ltd., H1 2015 22

Kidney Fibrosis-Pipeline by Lpath, Inc., H1 2015 23

Kidney Fibrosis-Pipeline by ProMetic Life Sciences Inc., H1 2015 24

Kidney Fibrosis-Pipeline by Raptor Pharmaceuticals Corp., H1 2015 25

Kidney Fibrosis-Pipeline by Regulus Therapeutics Inc., H1 2015 26

Kidney Fibrosis-Pipeline by RestorGenex Corporation, H1 2015 27

Kidney Fibrosis-Pipeline by Tobira Therapeutics, Inc., H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Mechanism of Action, H1 2015 33

Number of Products by Stage and Route of Administration, H1 2015 35

Number of Products by Stage and Molecule Type, H1 2015 37

Kidney Fibrosis Therapeutics-Recent Pipeline Updates, H1 2015 67

Kidney Fibrosis-Dormant Projects, H1 2015 88

List of Figures

Number of Products under Development for Kidney Fibrosis, H1 2015 9

Number of Products under Development for Kidney Fibrosis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 30

Number of Products by Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Top 10 Routes of Administration, H1 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35

Number of Products by Top 10 Molecule Types, H1 2015 36

Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

AbbVie Inc.

Angion Biomedica Corp.


BioLineRx, Ltd.

BiOrion Technologies B.V.

Galectin Therapeutics, Inc.

GNI Group Ltd.

Lpath, Inc.

ProMetic Life Sciences Inc.

Raptor Pharmaceuticals Corp.

Regulus Therapeutics Inc.

RestorGenex Corporation

Tobira Therapeutics, Inc.

Kidney Fibrosis Therapeutic Products under Development, Key Players in Kidney Fibrosis Therapeutics, Kidney Fibrosis Pipeline Overview, Kidney Fibrosis Pipeline, Kidney Fibrosis Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]